Access has commenced commercial launch of MuGard in Greece. Under a license from Access, SpePharm is responsible for manufacturing, regulatory approval and commercialization in 27 countries of Europe.
Additionally, the company said that two MuGard patents have been issued from the US Patent and Trademark Office, as US Patent numbers 7544348 and 7547433. The second patent includes claims on formulations with actives against mucocutaneous disorders, which provides protection of product line extensions.
MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many anticancer treatments. MuGard forms a protective coating over the oral mucosa when swirled gently around the mouth.